Nuvation Bio Inc (NUVB) Financial

Nuvation Bio, Inc. is a biopharmaceutical company tackling some of the unmet needs in oncology by developing differentiated and novel therapeutic candidates. The company is headquartered in San Francisco, California and currently employs 220 full-time employees. The company went IPO on 2020-07-01. The firm is engaged in tackling the unmet needs in oncology by developing differentiated and therapeutic candidates. The firm is advancing multiple clinical-stage candidates, including a ROS1 inhibitor, a mutant isocitrate dehydrogenase 1 (mIDH1) inhibitor, a bromodomain and extra-terminal (BET) inhibitor, and a drug-drug conjugate (DDC). Its portfolio of development candidates includes taletrectinib (ROS1), safusidenib (mIDH1), NUV-868 (BET), and NUV-1511 (DDC). Taletrectinib is an oral, potent, CNS-active, selective, ROS1 inhibitor specifically designed for the potential treatment of ROS1-positive non-small cell lung cancer (NSCLC). Safusidenib is an oral, potent, targeted inhibitor of mIDH1 being evaluated in a global Phase II trial in patients with low-grade IDH1-mutant glioma. NUV-868 is a BD2-selective oral small molecule BET inhibitor, that inhibits BRD4. The company is conducting Phase I/II study of NUV-1511.